Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17 beta -estradiol/trimegestone versus 1 or 2 mg 17 beta -estradiol/norethisterone acetate in postmenopausal women
Authors:
- 1 January 2005
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 21 (3) , 142-148
Abstract
Objective. To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17β-estradiol (17β-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17β-E2 and norethisterone acetate (NETA) regimens. Study design. This was a double-blind, randomized, multicenter study conducted in 12 European countries and Israel over a 2-year period. Healthy postmenopausal women with an intact uterus were given either 1 mg 17β-E2/0.125 mg TMG, 2 mg 17β-E2/1 mg NETA or 1 mg 17β-E2/0.5 mg NETA for up to 26 cycles, each of 28 days. Results. The percentage of amenorrheic women was greater in most cycles up to cycle 13 in the 1 mg 17β-E2/0.125 mg TMG group than in the comparator groups. The mean number of bleeding days was similar in the 1 mg 17β-E2/0.125 mg TMG and the 1 mg 17β-E2/0.5 mg NETA groups, but greater in the 2 mg 17β-E2/1 mg NETA group. No endometrial hyperplasia was observed for any group. Conclusion. Continuous combined 1 mg 17β-E2/0.125 mg TMG exhibits a more favorable bleeding profile than 1 mg 17β-E2/0.5 mg NETA up to 1 year, while providing an adequate protective effect on the endometrium.Keywords
This publication has 26 references indexed in Scilit:
- The preclinical biology of a new potent and selective progestin: trimegestoneSteroids, 2003
- Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetateClimacteric, 2001
- Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging studyHuman Reproduction, 1999
- The pharmacological profile of a novel norpregnane progestin (trimegestone)Gynecological Endocrinology, 1999
- Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens aloneAmerican Journal of Obstetrics and Gynecology, 1994
- Progestagen supplementation of exogenous oestrogens and risk of endometrial cancerThe Lancet, 1991
- The Impact of Different Doses of Estrogen and Progestin on Mood and Sexual Behavior in Postmenopausal Women*The Journal of Clinical Endocrinology & Metabolism, 1991
- Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.BMJ, 1989
- A new combination of conjugated equine oestrogens and medroxyprogesterone for treatment of climacteric complaintsMaturitas, 1984
- The effects of oestrogens and progestogens on the postmenopausal endometriumMaturitas, 1978